Product candidate
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
2022 Milestones
4Q 2022 / 1Q 2023Initiation of multi-cohort phase 2 trial
PD-1 Refractory Melanoma Re-challenge combination w/anti PD-1
ONCOS-102
1H 2022Full study data presented at ASCO, incl. 30 month OS rate
Mesothelioma Combination w/Standard-of-Care (SoC)
2H 2022First patient visit (EU)
Multiple Myeloma TG01 / QS-21
Mutant KRAS
2H 2022
First patient visit (USA)
Undisclosed indication TG01 / QS-21
circular RNA
2H 2022
Pre-clinical proof-of-concept data
Cancer Indication: PD-1 Refractory Melanoma
Combination with: Re-challenge combination w/anti PD-1
Product candidate: ONCOS-102
Next expected event: 4Q 2022 / 1Q 2023
Initiation of multi-cohort phase 2 trial
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Mesothelioma
Combination with: Combination w/Standard-of-Care (SoC)
Product candidate: ONCOS-102
Next expected event: 1H 2022
Full study data presented at ASCO, incl. 30 month OS rate
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Multiple Myeloma
Combination with: TG01 / QS-21
Product candidate: Mutant KRAS
Next expected event: 2H 2022
First patient visit (EU)
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Undisclosed indication
Combination with: TG01 / QS-21
Product candidate: Mutant KRAS
Next expected event: 2H 2022
First patient visit (USA)
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication:
Combination with: -
Product candidate: circular RNA
Next expected event: 2H 2022
Pre-clinical proof-of-concept data
Discovery
IND-enabling
Phase 1
Phase 2
Phase 3 / pivotal